SpliceBio secured $135 million in Series B funding to support clinical development of its lead gene therapy candidate, SB-007, for Stargardt disease. The dual AAV vector therapy aims to deliver the full-length ABCA4 gene, addressing limitations of existing gene therapies for inherited retinal conditions. This funding round reflects ongoing investor confidence in gene therapies targeting rare retinal diseases and supports SpliceBio's clinical trial progression.